The vaccines market is expected to reach 63.66 billion USD in 2030, up from 50.46 billion USD in 2025, growing at a CAGR of 4.8% during the forecast period. Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth vaccines.
In 2024, by disease indication, the pneumococcal segment accounted for the largest share of the vaccines market.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, and other disease indications. In 2022, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits outcomes.
In 2024, by type, the multivalent vaccines segment accounted for the largest share of the vaccines market.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2024, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance comes from the ability of multivalent vaccines to provide protection against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
In 2024, the Asia Pacific was the fastest growing region in the Vaccines market.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
• By Region: North America -35%, Europe - 25%, Asia Pacific -20%, Latin America -10%, the Middle East & Africa- 10%
GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India) are some of the key companies offering Vaccines.
Research Coverage
This research report categorizes the Vaccines market by technology (conjugate vaccine, recombinant vaccine, inactivated & subunit vaccine, live attenuated vaccine, toxoid vaccine, viral vector vaccine, mRNA vaccine, and other vaccines), type (monovalent vaccines, multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccine, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSA, other disease indications), route of administration (intramuscular & subcutaneous, oral, other routes), end user (pediatric vaccines, adult vaccines), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. Competitive analysis of top players and upcoming startups within the vaccines market ecosystem is included in this report. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the Vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (strong emphasis on investment and launch of novel vaccines, rising prevalence of infectious disease, expanding immunization programs, advancements in vaccine technology and robust government support & funding for the development of vaccines), restraints (High development cost, patent expiry ), opportunities (Increased focus on therapeutic vaccines, robust & strong pipeline) and challenges (Stringent regulatory processes, vaccine supply shortage, frequent product recall)
• Product Development/Innovation: Detailed insights on newly launched Products, and technological assessment of the Vaccines market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Vaccines market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Vaccines market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi fei Biological (China), Indian Immunologicals Ltd (India), among others, in the vaccines market. The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments, and funding activities, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines sector market.
圖表清單 List of Tables & Figures
TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS 40
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 53
TABLE 3 VACCINES MARKET: RISK ASSESSMENT ANALYSIS 57
TABLE 4 VACCINES MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES 69
TABLE 5 VACCINES MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS 70
TABLE 6 VACCINES MARKET: IMPACT ANALYSIS 74
TABLE 7 NIH FUNDING FOR VACCINE RESEARCH, 2020–2024 (USD MILLION) 79
TABLE 8 MAJOR COST DRIVERS AND IMPACT ON COST OF GOODS SOLD (COGS) 80
TABLE 9 NOTABLE CANCER VACCINES IN CLINICAL TRIALS 83
TABLE 10 AVERAGE SELLING PRICE TREND OF PEDIATRIC VACCINES, BY KEY PLAYER,
2023–2025 (USD) 88
TABLE 11 AVERAGE SELLING PRICE TREND OF ADULT VACCINES, BY KEY PLAYER,
2023–2025 (USD) 89
TABLE 12 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2021–2023 (USD) 92
TABLE 13 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR RSV 99
TABLE 14 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR PNEUMOCOCCAL DISEASE 102
TABLE 15 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR INFLUENZA 104
TABLE 16 KEY PIPELINE VACCINES: GSK PLC 105
TABLE 17 KEY PIPELINE VACCINES: MERCK & CO., INC. 106
TABLE 18 KEY PIPELINE VACCINES: PFIZER INC. 106
TABLE 19 KEY PIPELINE VACCINES: SANOFI S.A. 106
TABLE 20 VACCINES MARKET: ROLE IN ECOSYSTEM 107
TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 109
TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 110
TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 111
TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 111
TABLE 25 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 112
TABLE 26 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 112
TABLE 27 IMPORT VALUE FOR HS CODE 300220, 2020–2024 (USD THOUSAND) 114
TABLE 28 IMPORT VOLUME FOR HS CODE 300220, 2020–2024 (TONS) 115
TABLE 29 EXPORT VALUE FOR HS CODE 300220, 2020–2024 (USD THOUSAND) 116
TABLE 30 EXPORT VOLUME FOR HS CODE 300220, 2020–2024 (TONS) 117
TABLE 31 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 118
TABLE 32 VACCINES MARKET: INDICATIVE LIST OF PATENTS, 2025 122
TABLE 33 VACCINES MARKET: LIST OF CONFERENCES & EVENTS, 2025–2026 123
TABLE 34 BUYING CRITERIA FOR VACCINES, BY END USER 125
TABLE 35 KEY COMPANIES IMPLEMENTING AI 128
TABLE 36 US-ADJUSTED RECIPROCAL TARIFF RATES 129
TABLE 37 NUMBER OF VACCINES DELIVERED BY UNICEF, 2023–2025 133
TABLE 38 WHO VACCINE PURCHASE DATABASE, BY PROCUREMENT MECHANISM,
2021–2023 134
TABLE 39 WHO VACCINE PURCHASE DATABASE, BY MANUFACTURER, 2021–2023 134
TABLE 40 WHO VACCINE PURCHASE DATABASE, BY INDICATION, 2021–2023 135
TABLE 41 WHO VACCINE PURCHASE DATABASE, BY REGION, 2021–2023 136
TABLE 42 VACCINE PRODUCTION CAPACITY, BY KEY PLAYER, 2024 138
TABLE 43 VACCINES MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION) 140
TABLE 44 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 142
TABLE 45 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2023–2030 (USD MILLION) 142
TABLE 46 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 47 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 48 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 49 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 50 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 146
TABLE 51 INFLUENZA VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 52 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 53 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 54 ASIA PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 55 LATIN AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 149
TABLE 56 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 150
TABLE 57 COMBINATION VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 58 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 59 EUROPE: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 60 ASIA PACIFIC: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 61 LATIN AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 62 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 154
TABLE 63 HPV VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 64 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 155
TABLE 65 EUROPE: HPV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 66 ASIA PACIFIC: HPV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 67 LATIN AMERICA: HPV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 68 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 158
TABLE 69 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2023–2030 (USD MILLION) 158
TABLE 70 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 71 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 72 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 73 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 74 LIST OF COMMERCIALLY AVAILABLE HERPES ZOSTER VACCINES 162
TABLE 75 HERPES ZOSTER VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 76 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 77 EUROPE: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 78 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 79 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 80 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 164
TABLE 81 ROTAVIRUS VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 82 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 165
TABLE 83 EUROPE: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 166
TABLE 84 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 166
TABLE 85 LATIN AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 167
TABLE 86 TOP 10 COUNTRIES WITH MEASLES OUTBREAKS, JANUARY 2025–JULY 2025 168
TABLE 87 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 168
TABLE 88 MMR VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 89 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 169
TABLE 90 EUROPE: MMR VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 91 ASIA PACIFIC: MMR VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 92 LATIN AMERICA: MMR VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 171
TABLE 93 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 172
TABLE 94 VARICELLA VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 95 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 172
TABLE 96 EUROPE: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 97 ASIA PACIFIC: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 98 LATIN AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 174
TABLE 99 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 175
TABLE 100 HEPATITIS VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 101 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 176
TABLE 102 EUROPE: HEPATITIS VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 103 ASIA PACIFIC: HEPATITIS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 177
TABLE 104 LATIN AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 177
TABLE 105 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 178
TABLE 106 DTP VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 107 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 179
TABLE 108 EUROPE: DTP VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 109 ASIA PACIFIC: DTP VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 110 LATIN AMERICA: DTP VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 180
TABLE 111 POLIO VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 181
TABLE 112 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 182
TABLE 113 EUROPE: POLIO VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 114 ASIA PACIFIC: POLIO VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 115 LATIN AMERICA: POLIO VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 183
TABLE 116 RSV VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 117 NORTH AMERICA: RSV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 185
TABLE 118 EUROPE: RSV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 119 ASIA PACIFIC: RSV VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 120 LATIN AMERICA: RSV VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 187
TABLE 121 COVID-19 VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 188
TABLE 122 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 188
TABLE 123 EUROPE: COVID-19 VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 124 ASIA PACIFIC: COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 189
TABLE 125 LATIN AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 190
TABLE 126 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 190
TABLE 127 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2023–2030 (USD MILLION) 191
TABLE 128 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 129 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 130 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 131 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 132 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY,
2023–2030 (USD MILLION) 195
TABLE 133 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 197
TABLE 134 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 135 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 136 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 137 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 138 EXAMPLES OF RECOMBINANT VACCINES 200
TABLE 139 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 200
TABLE 140 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 141 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 142 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 143 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 144 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 203
TABLE 145 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2023–2030 (USD MILLION) 204
TABLE 146 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 147 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 148 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 149 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET
(EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 150 EXAMPLES OF LIVE ATTENUATED VACCINES 207
TABLE 151 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2023–2030 (USD MILLION) 208
TABLE 152 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 153 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 154 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 155 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 156 EXAMPLES OF TOXOID VACCINES 211
TABLE 157 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 211
TABLE 158 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 159 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 160 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 161 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 162 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 215
TABLE 163 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 164 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 165 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 166 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 167 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 217
TABLE 168 MRNA COVID-19 VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 219
TABLE 169 NORTH AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 219
TABLE 170 EUROPE: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 220
TABLE 171 ASIA PACIFIC: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 220
TABLE 172 LATIN AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 221
TABLE 173 VIRAL VECTOR COVID-19 VACCINES MARKET, BY REGION,
2023–2030 (USD MILLION) 222
TABLE 174 NORTH AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 175 EUROPE: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 223
TABLE 176 ASIA PACIFIC: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 223
TABLE 177 LATIN AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 224
TABLE 178 OTHER COVID-19 VACCINES MARKET, BY REGION, 2023–2030 (USD MILLION) 224
TABLE 179 NORTH AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 225
TABLE 180 EUROPE: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 225
TABLE 181 ASIA PACIFIC: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 226
TABLE 182 LATIN AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 226
TABLE 183 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 184 EXAMPLES OF MULTIVALENT VACCINES 229
TABLE 185 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 230
TABLE 186 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 230
TABLE 187 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 231
TABLE 188 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 231
TABLE 189 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 232
TABLE 190 EXAMPLES OF MONOVALENT VACCINES 233
TABLE 191 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 234
TABLE 192 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 234
TABLE 193 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 235
TABLE 194 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 235
TABLE 195 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 236
TABLE 196 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 238
TABLE 197 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR &
SUBCUTANEOUS ADMINISTRATION 239
TABLE 198 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 240
TABLE 199 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 240
TABLE 200 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 241
TABLE 201 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 241
TABLE 202 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2023–2030 (USD MILLION) 242
TABLE 203 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 243
TABLE 204 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 243
TABLE 205 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 244
TABLE 206 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 244
TABLE 207 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 245
TABLE 208 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING
COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 246
TABLE 209 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 246
TABLE 210 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 247
TABLE 211 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 247
TABLE 212 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 248
TABLE 213 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2023–2030 (USD MILLION) 250
TABLE 214 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 251
TABLE 215 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 252
TABLE 216 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 252
TABLE 217 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 253
TABLE 218 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 253
TABLE 219 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2023–2030 (USD MILLION) 254
TABLE 220 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 255
TABLE 221 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 255
TABLE 222 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 256
TABLE 223 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 256
TABLE 224 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2023–2030 (USD MILLION) 258
TABLE 225 NORTH AMERICA: KEY MACROINDICATORS 259
TABLE 226 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 260
TABLE 227 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 261
TABLE 228 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 229 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 262
TABLE 230 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 263
TABLE 231 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 263
TABLE 232 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 264
TABLE 233 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 265
TABLE 234 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 265
TABLE 235 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 266
TABLE 236 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2023–2030 (USD MILLION) 266
TABLE 237 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 267
TABLE 238 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 268
TABLE 239 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 268
TABLE 240 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 269
TABLE 241 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 269
TABLE 242 EUROPE: KEY MACROINDICATORS 270
TABLE 243 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2023–2030 (USD MILLION) 271
TABLE 244 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 271
TABLE 245 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 272
TABLE 246 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 272
TABLE 247 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 273
TABLE 248 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 273
TABLE 249 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 275
TABLE 250 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 275
TABLE 251 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 276
TABLE 252 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 277
TABLE 253 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 277
TABLE 254 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 278
TABLE 255 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 279
TABLE 256 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 279
TABLE 257 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 280
TABLE 258 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2023–2030 (USD MILLION) 280
TABLE 259 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 281
TABLE 260 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 282
TABLE 261 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 282
TABLE 262 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 283
TABLE 263 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 283
TABLE 264 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 284
TABLE 265 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 266 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 285
TABLE 267 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 286
TABLE 268 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 286
TABLE 269 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 287
TABLE 270 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 287
TABLE 271 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 288
TABLE 272 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 289
TABLE 273 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 289
TABLE 274 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 290
TABLE 275 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2023–2030 (USD MILLION) 290
TABLE 276 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 291
TABLE 277 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 292
TABLE 278 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 292
TABLE 279 ASIA PACIFIC: KEY MACROINDICATORS 294
TABLE 280 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 295
TABLE 281 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 295
TABLE 282 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 283 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 296
TABLE 284 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 297
TABLE 285 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 297
TABLE 286 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 298
TABLE 287 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 299
TABLE 288 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 299
TABLE 289 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 300
TABLE 290 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 300
TABLE 291 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 302
TABLE 292 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 302
TABLE 293 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 303
TABLE 294 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 304
TABLE 295 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 304
TABLE 296 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 305
TABLE 297 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 306
TABLE 298 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 306
TABLE 299 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 307
TABLE 300 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 307
TABLE 301 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 308
TABLE 302 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 309
TABLE 303 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 309
TABLE 304 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 310
TABLE 305 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 310
TABLE 306 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 311
TABLE 307 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2023–2030 (USD MILLION) 312
TABLE 308 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 312
TABLE 309 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 313
TABLE 310 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 313
TABLE 311 LATIN AMERICA: KEY MACROINDICATORS 314
TABLE 312 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2023–2030 (USD MILLION) 315
TABLE 313 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 315
TABLE 314 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 316
TABLE 315 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2023–2030 (USD MILLION) 316
TABLE 316 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 317
TABLE 317 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 317
TABLE 318 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 318
TABLE 319 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 318
TABLE 320 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 319
TABLE 321 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 320
TABLE 322 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 320
TABLE 323 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 321
TABLE 324 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 322
TABLE 325 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 322
TABLE 326 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 323
TABLE 327 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 323
TABLE 328 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 324
TABLE 329 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 324
TABLE 330 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 325
TABLE 331 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 326
TABLE 332 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 326
TABLE 333 MIDDLE EAST: KEY MACROINDICATORS 327
TABLE 334 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2023–2030 (USD MILLION) 328
TABLE 335 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2023–2030 (USD MILLION) 328
TABLE 336 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 329
TABLE 337 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 330
TABLE 338 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2023–2030 (USD MILLION) 330
TABLE 339 AFRICA: KEY MACROINDICATORS 331
TABLE 340 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2023–2030 (USD MILLION) 332
TABLE 341 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2023–2030 (USD MILLION) 332
TABLE 342 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2023–2030 (USD MILLION) 333
TABLE 343 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 334
TABLE 344 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2023–2030 (USD MILLION) 334
TABLE 345 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, JANUARY 2022−AUGUST 2025 335
TABLE 346 VACCINES MARKET: DEGREE OF COMPETITION 340
TABLE 347 VACCINES MARKET: REGION FOOTPRINT 345
TABLE 348 VACCINES MARKET: TECHNOLOGY FOOTPRINT 346
TABLE 349 VACCINES MARKET: TYPE FOOTPRINT 347
TABLE 350 VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 348
TABLE 351 VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 351
TABLE 352 VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 352
TABLE 353 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 355
TABLE 354 VACCINES MARKET: DEALS, JANUARY 2022–AUGUST 2025 356
TABLE 355 VACCINES MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 357
TABLE 356 GSK PLC: COMPANY OVERVIEW 358
TABLE 357 GSK PLC: PRODUCTS OFFERED 359
TABLE 358 GSK PLC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 362
TABLE 359 GSK PLC: DEALS, JANUARY 2022–AUGUST 2025 363
TABLE 360 GSK PLC: EXPANSIONS, JANUARY 2022–AUGUST 2025 364
TABLE 361 MERCK & CO., INC.: COMPANY OVERVIEW 365
TABLE 362 MERCK & CO., INC.: PRODUCTS OFFERED 366
TABLE 363 MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 368
TABLE 364 MERCK & CO., INC.: DEALS, JANUARY 2022–AUGUST 2025 369
TABLE 365 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 369
TABLE 366 PFIZER INC.: COMPANY OVERVIEW 371
TABLE 367 PFIZER INC.: PRODUCTS OFFERED 372
TABLE 368 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 374
TABLE 369 PFIZER INC.: DEALS, JANUARY 2022–AUGUST 2025 376
TABLE 370 SANOFI: COMPANY OVERVIEW 377
TABLE 371 SANOFI: PRODUCTS OFFERED 378
TABLE 372 SANOFI: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 380
TABLE 373 SANOFI: DEALS, JANUARY 2022–AUGUST 2025 380
TABLE 374 SANOFI: EXPANSIONS, JANUARY 2022–AUGUST 2025 381
TABLE 375 SANOFI: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 382
TABLE 376 CSL: COMPANY OVERVIEW 383
TABLE 377 CSL: PRODUCTS OFFERED 385
TABLE 378 CSL: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 385
TABLE 379 CSL: DEALS, JANUARY 2022–AUGUST 2025 386
TABLE 380 CSL: EXPANSIONS, JANUARY 2022–AUGUST 2025 387
TABLE 381 EMERGENT: COMPANY OVERVIEW 388
TABLE 382 EMERGENT: PRODUCTS OFFERED 390
TABLE 383 EMERGENT: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 391
TABLE 384 EMERGENT: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 391
TABLE 385 JOHNSON & JOHNSON SERVICES INC.: COMPANY OVERVIEW 393
TABLE 386 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS OFFERED 394
TABLE 387 JOHNSON & JOHNSON SERVICES INC.: DEALS, JANUARY 2022–AUGUST 2025 395
TABLE 388 ASTRAZENECA: COMPANY OVERVIEW 396
TABLE 389 ASTRAZENECA: PRODUCTS OFFERED 397
TABLE 390 ASTRAZENECA: DEALS, JANUARY 2022–AUGUST 2025 398
TABLE 391 ASTRAZENECA: EXPANSIONS, JANUARY 2022–AUGUST 2025 398
TABLE 392 ASTRAZENECA: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 399
TABLE 393 SERUM INSTITUTE OF INDIA PVT., LTD.: COMPANY OVERVIEW 400
TABLE 394 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED
(SUPPLIED OVERSEAS) 400
TABLE 395 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS OFFERED (SUPPLIED IN INDIA) 402
TABLE 396 SERUM INSTITUTE OF INDIA PVT., LTD.: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 403
TABLE 397 SERUM INSTITUTE OF INDIA PVT., LTD.: DEALS, JANUARY 2022–AUGUST 2025 404
TABLE 398 SERUM INSTITUTE OF INDIA PVT., LTD.: EXPANSIONS,
JANUARY 2022–AUGUST 2025 404
TABLE 399 BAVARIAN NORDIC: COMPANY OVERVIEW 405
TABLE 400 BAVARIAN NORDIC: PRODUCTS OFFERED 406
TABLE 401 BAVARIAN NORDIC: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 407
TABLE 402 BAVARIAN NORDIC: DEALS, JANUARY 2022–AUGUST 2025 408
TABLE 403 BAVARIAN NORDIC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 410
TABLE 404 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY OVERVIEW 411
TABLE 405 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCTS OFFERED 411
TABLE 406 MITSUBISHI TANABE PHARMA CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 412
TABLE 407 MITSUBISHI TANABE PHARMA CORPORATION: DEALS,
JANUARY 2022–AUGUST 2025 412
TABLE 408 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 413
TABLE 409 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED 414
TABLE 410 DAIICHI SANKYO COMPANY, LIMITED: DEALS, JANUARY 2022–AUGUST 2025 415
TABLE 411 PANACEA BIOTEC: COMPANY OVERVIEW 416
TABLE 412 PANACEA BIOTEC: PRODUCTS OFFERED 417
TABLE 413 PANACEA BIOTEC: DEALS, JANUARY 2022–AUGUST 2025 418
TABLE 414 BIOLOGICAL E LIMITED: COMPANY OVERVIEW 419
TABLE 415 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INDIAN MARKET) 419
TABLE 416 BIOLOGICAL E LIMITED: PRODUCTS OFFERED (INTERNATIONAL MARKET) 420
TABLE 417 BIOLOGICAL E LIMITED: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 421
TABLE 418 BIOLOGICAL E LIMITED: DEALS, JANUARY 2022–AUGUST 2025 422
TABLE 419 BIOLOGICAL E LIMITED: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 422
TABLE 420 BHARAT BIOTECH: COMPANY OVERVIEW 423
TABLE 421 BHARAT BIOTECH: PRODUCTS OFFERED 423
TABLE 422 BHARAT BIOTECH: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–AUGUST 2025 424
TABLE 423 BHARAT BIOTECH: DEALS, JANUARY 2022–AUGUST 2025 425
TABLE 424 NOVAVAX: COMPANY OVERVIEW 426
TABLE 425 NOVAVAX: PRODUCTS OFFERED 427
TABLE 426 NOVAVAX: PRODUCT APPROVALS, JANUARY 2022–AUGUST 2025 427
TABLE 427 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW 430
TABLE 428 INOVIO PHARMACEUTICALS: PRODUCTS OFFERED 431
TABLE 429 INOVIO PHARMACEUTICALS: OTHER DEVELOPMENTS,
JANUARY 2022–AUGUST 2025 431
TABLE 430 SINOVAC: COMPANY OVERVIEW 432
TABLE 431 INCEPTA PHARMACEUTICALS LTD.: COMPANY OVERVIEW 433
TABLE 432 VALNEVA SE: COMPANY OVERVIEW 435
TABLE 433 VBI VACCINE INC.: COMPANY OVERVIEW 436
TABLE 434 BIO FARMA: COMPANY OVERVIEW 437
TABLE 435 MICROGEN: COMPANY OVERVIEW 439
TABLE 436 ZHI FEI BIOLOGICAL: COMPANY OVERVIEW 440
TABLE 437 INDIAN IMMUNOLOGICALS LIMITED: COMPANY OVERVIEW 441
FIGURE 1 VACCINES MARKET SEGMENTATION & REGIONAL SCOPE 39
FIGURE 2 VACCINES MARKET: RESEARCH DESIGN 43
FIGURE 3 VACCINES MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 45
FIGURE 4 VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 46
FIGURE 5 GLOBAL MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS
(BOTTOM-UP APPROACH), 2024 47
FIGURE 6 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS, 2024 48
FIGURE 7 ILLUSTRATIVE EXAMPLE OF INFLUENZA VACCINES: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2024 49
FIGURE 8 VACCINES MARKET: MARKET SIZE VALIDATION FROM PRIMARY SOURCES 50
FIGURE 9 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 51
FIGURE 10 VACCINES MARKET: CAGR PROJECTION (2025–2030) 53
FIGURE 11 VACCINES MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS 54
FIGURE 12 DATA TRIANGULATION METHODOLOGY 55
FIGURE 13 VACCINES MARKET, BY DISEASE INDICATION, 2025 VS. 2030 (USD MILLION) 58
FIGURE 14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 59
FIGURE 15 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2025 VS. 2030 (USD MILLION) 60
FIGURE 16 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION) 61
FIGURE 17 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2025 VS. 2030 (USD MILLION) 62
FIGURE 18 REGIONAL SNAPSHOT OF VACCINES MARKET (EXCLUDING COVID-19 VACCINES) 63
FIGURE 19 FOCUS ON VACCINE DEVELOPMENT & LAUNCHES TO PROPEL MARKET GROWTH 66
FIGURE 20 US AND MULTIVALENT VACCINES SEGMENT COMMANDED LARGEST MARKET SHARES IN 2024 67
FIGURE 21 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 68
FIGURE 22 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 73
FIGURE 23 US: NOVEL INFLUENZA A VIRUS CASES, BY SEASON (2010–2011 TO
2023–2024 SEASON) 76
FIGURE 24 MANUFACTURING-RELATED PARAMETERS INCLUDED IN COST MODEL 81
FIGURE 25 US: ESTIMATED NUMBER OF NEW CANCER CASES AND DEATHS BY SITE, 2025 82
FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 87
FIGURE 27 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION,
2023–2025 (USD) 91
FIGURE 28 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE 97
FIGURE 29 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 98
FIGURE 30 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 99
FIGURE 31 VACCINES MARKET: ECOSYSTEM MARKET MAP 107
FIGURE 32 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 118
FIGURE 33 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINES PATENTS, 2014–2024 121
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 124
FIGURE 35 KEY BUYING CRITERIA FOR END USERS 125
FIGURE 36 BIOPHARMA MERGER & ACQUISITION (M&A) ACTIVITIES: INVESTMENT & FUNDING SCENARIO, 2020−2024 126
FIGURE 37 VACCINES DEAL ACTIVITIES: INVESTMENT & FUNDING SCENARIO, 2017−2023 126
FIGURE 38 AI USE CASES 128
FIGURE 39 NORTH AMERICA: VACCINES MARKET SNAPSHOT
(EXCLUDING COVID-19 VACCINES) 260
FIGURE 40 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 294
FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET,
2020–2024 (USD BILLION) 339
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET (2024) 340
FIGURE 43 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 343
FIGURE 44 VACCINES MARKET: COMPANY FOOTPRINT 344
FIGURE 45 VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 350
FIGURE 46 EV/EBITDA OF KEY VENDORS 353
FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 353
FIGURE 48 VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 354
FIGURE 49 GSK PLC: COMPANY SNAPSHOT (2024) 359
FIGURE 50 MERCK & CO., INC.: COMPANY SNAPSHOT (2024) 366
FIGURE 51 PFIZER INC.: COMPANY SNAPSHOT (2024) 372
FIGURE 52 SANOFI: COMPANY SNAPSHOT (2024) 378
FIGURE 53 CSL: COMPANY SNAPSHOT (2024) 384
FIGURE 54 EMERGENT: COMPANY SNAPSHOT (2024) 389
FIGURE 55 JOHNSON & JOHNSON SERVICES INC.: COMPANY SNAPSHOT (2024) 394
FIGURE 56 ASTRAZENECA: COMPANY SNAPSHOT (2024) 397
FIGURE 57 BAVARIAN NORDIC: COMPANY SNAPSHOT (2024) 406
FIGURE 58 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024) 414
FIGURE 59 PANACEA BIOTEC: COMPANY SNAPSHOT (2024) 416
FIGURE 60 NOVAVAX: COMPANY SNAPSHOT (2024) 426
FIGURE 61 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 430